#kidney

Internal documents show Gilead held off on developing new therapies, such as Descovy, a potentially less toxic version of Truvada.

Jean-Michel Molina, MD, with the French ANRS-PREVENIR Study Group assessed the impact of different PrEP dosing regimens on kidney function.

Changes in kidney function were small for those using TDF/FTC either daily or on-demand for HIV prevention.

HIV-positive heart transplant recipient (and cancer survivor) Miriam Nieves meets the family of the HIV-positive donor, Brittany Newton.

The heart transplant recipient—a woman in her sixties—also received a new kidney during the surgery at a Bronx, New York, hospital.

People with certain blood types face a greater risk for blood clots, bleeding, kidney stones and pregnancy-induced hypertension.

ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.

A mid-stage trial of the experimental drug islatravir plus Pifeltro did not see notable shifts in measures of kidney function.

Plus: Watch a video interview series exploring the intersections between HIV and COVID-19.

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

A long-term study found that kidney transplants between people with HIV have high success rates.

Rates of HIV acquisition were very low among people taking Descovy or Truvada, but Descovy had less effect on kidneys and bones.

The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.